MENU
ANIP
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

ANIP stock forecast, quote, news & analysis

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company... Show more

ANIP
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for ANIP with price predictions
Jul 30, 2026

Aroon Indicator for ANIP shows an upward move is likely

ANIP's Aroon Indicator triggered a bullish signal on July 13, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 237 similar instances where the Aroon Indicator showed a similar pattern. In of the 237 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for ANIP just turned positive on July 30, 2026. Looking at past instances where ANIP's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ANIP advanced for three days, in of 299 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Momentum Indicator moved below the 0 level on July 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANIP as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

ANIP moved below its 50-day moving average on July 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ANIP crossed bearishly below the 50-day moving average on July 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANIP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ANIP broke above its upper Bollinger Band on July 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ANIP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.204) is normal, around the industry mean (47.407). P/E Ratio (20.266) is within average values for comparable stocks, (104.259). ANIP's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.800). ANIP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.035). P/S Ratio (1.853) is also within normal values, averaging (116.066).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.16B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 1%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 19%. BHC experienced the highest price growth at 36%, while SXTC experienced the biggest fall at -78%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 86%. For the same stocks of the Industry, the average monthly volume growth was 160% and the average quarterly volume growth was 63%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 63
Price Growth Rating: 59
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 12 (-100 ... +100)
View a ticker or compare two or three
ANIP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a manufacturer of branded and generic prescription pharmaceuticals

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Pharmaceuticals Other
Address
210 Main Street West
Phone
+1 218 634-3500
Employees
970
Web
https://www.anipharmaceuticals.com
Aroon Indicator for ANIP shows an upward move is likely